commercialize LRT which is a repurposing of a lipid emulsion that is FDA and EMA approved as a nutritional supplement. ResQ Pharma plans to file applications for market approval for both the EU and USA by the 1st quarter of 2017. Applications for Orphan Drug Designation are pending with both the FDA and EMA currently.

This lipid emulsion has been used around the world since 2010 as Lipid Rescue Therapy (LRT). The problem is that it is not regulatorily approved as a treatment for overdoses and poisonings. Therefore it cannot be marketed and many in the healthcare community are not aware of product. Approximately 47,000 people died in 2015 from drug overdoses and poisonings, approximately 40% likely treatable with LRT.